EML4 and non-small cell lung carcinoma: ALK rearrangements occur in approximately 3–10% of NSCLC patients, and echinoderm microtubule-associated protein-like 4 (EML4) is the most common ALK fusion partner in lung adenocarcinoma (2, 3).